NASDAQ:CYTK - Cytokinetics Stock Price, Forecast & News

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CYTK shares have decreased by 2.3% and is now trading at $11.75. View which stocks have been mosted impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cytokinetics.

Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Cytokinetics.

Cytokinetics, Inc. (NASDAQ:CYTK) issued its earnings results on Tuesday, March, 3rd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.44) by $0.08. The biopharmaceutical company earned $5.21 million during the quarter, compared to analysts' expectations of $7.19 million. Cytokinetics had a negative net margin of 452.92% and a negative return on equity of 10,351.99%. View Cytokinetics' earnings history.

Cytokinetics issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, March, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $18-22 million, compared to the consensus revenue estimate of $28.03 million.

6 analysts have issued 1 year target prices for Cytokinetics' shares. Their forecasts range from $16.00 to $30.00. On average, they expect Cytokinetics' stock price to reach $22.17 in the next twelve months. This suggests a possible upside of 88.7% from the stock's current price. View analysts' price targets for Cytokinetics.

Press coverage about CYTK stock has been trending negative this week, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cytokinetics earned a news impact score of -2.1 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutCytokinetics.

Cytokinetics saw a decline in short interest in March. As of March 13th, there was short interest totaling 7,830,200 shares, a decline of 6.1% from the February 27th total of 8,340,000 shares. Based on an average trading volume of 749,000 shares, the days-to-cover ratio is presently 10.5 days. Currently, 14.4% of the shares of the company are sold short. View Cytokinetics' Current Options Chain.

Some companies that are related to Cytokinetics include GW Pharmaceuticals PLC- (GWPH), Genmab A/S (GMAB), Ultragenyx Pharmaceutical (RARE), PPD (SDGR), HUTCHISON CHINA/S (HCM), PTC Therapeutics (PTCT), Myokardia (MYOK), Deciphera Pharmaceuticals (DCPH), Allakos (ALLK), Amicus Therapeutics (FOLD), ArQule (ARQL), Agios Pharmaceuticals (AGIO), ChemoCentryx (CCXI), Taro Pharmaceutical Industries (TARO) and Axsome Therapeutics (AXSM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Geron (GERN), TG Therapeutics (TGTX) and Progenics Pharmaceuticals (PGNX).

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BVF Inc. IL (12.20%), Driehaus Capital Management LLC (5.14%), Point72 Asset Management L.P. (5.13%), State Street Corp (4.30%), FMR LLC (3.02%) and Geode Capital Management LLC (1.35%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum and Value Fund L P Biotechnology. View institutional ownership trends for Cytokinetics.

CYTK stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Citigroup Inc., UBS Group AG, Pinnacle Associates Ltd., South Dakota Investment Council, Arizona State Retirement System, Chicago Equity Partners LLC, and Credit Suisse AG. Company insiders that have sold Cytokinetics company stock in the last year include Bvf Partners L P/Il, Fady Ibraham Malik, and Robert I Blum. View insider buying and selling activity for Cytokinetics.

CYTK stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, Point72 Asset Management L.P., Jennison Associates LLC, Jacobs Levy Equity Management Inc., Driehaus Capital Management LLC, State Street Corp, Goldman Sachs Group Inc., and Mirador Capital Partners LP. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology. View insider buying and selling activity for Cytokinetics.

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CYTK stock can currently be purchased for approximately $11.75.

Cytokinetics has a market capitalization of $698.54 million and generates $26.87 million in revenue each year. The biopharmaceutical company earns $-121,690,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Cytokinetics employs 130 workers across the globe. View additional information about Cytokinetics.

The official website for Cytokinetics is http://www.cytokinetics.com/.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]